2017
Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study
Loch A, Bewersdorf J, Kofink D, Ismail D, Abidin I, Veriah R. Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC Research Notes 2017, 10: 291. PMID: 28716156, PMCID: PMC5514478, DOI: 10.1186/s13104-017-2617-6.Peer-Reviewed Original ResearchConceptsStatistically significant differenceEffective management of hyperlipidemiaHealth care costsSignificant differenceUniversity of Malaya Medical CentreRetrospective cohort studyHDL cholesterol levelsManagement of hyperlipidemiaLipid lowering effectsIncreased health care costsAtorvastatin formulationsLowering cholesterol levelsSwitching patientsCare costsLDL cholesterolMethodsThis cross-sectionalCohort studyLipid profileTotal cholesterolGeneric atorvastatinDrug efficacyAtorvastatinMedical CentreCholesterol levelsPatients
2013
Characterization of Statin Dose Response in Electronic Medical Records
Wei W, Feng Q, Jiang L, Waitara M, Iwuchukwu O, Roden D, Jiang M, Xu H, Krauss R, Rotter J, Nickerson D, Davis R, Berg R, Peissig P, McCarty C, Wilke R, Denny J. Characterization of Statin Dose Response in Electronic Medical Records. Clinical Pharmacology & Therapeutics 2013, 95: 331-338. PMID: 24096969, PMCID: PMC3944214, DOI: 10.1038/clpt.2013.202.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAllelesAtorvastatinCholesterol, LDLCohort StudiesDatabases, FactualDose-Response Relationship, DrugElectronic Health RecordsGenotypeHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasLipid MetabolismLipidsPhenotypePolymorphism, Single NucleotidePyrrolesRandomized Controlled Trials as TopicSimvastatin
2007
Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy
Hinchcliff M, Varga J. Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy. Expert Review Of Clinical Immunology 2007, 3: 11-15. PMID: 20476946, DOI: 10.1586/1744666x.3.1.11.Peer-Reviewed Original ResearchSystemic sclerosisObliterative vasculopathyOpen-label clinical trialEfficacy of statinsChronic cardiovascular diseasePrecursor cellsSerious clinical manifestationsEndothelial precursor cellsChronic vasculopathyVascular obliterationClinical manifestationsVascular damageVascular precursor cellsClinical trialsTherapeutic roleCardiovascular diseaseEffective treatmentImpaired productionVasculopathySclerosisNovel targetStatinsDefective vasculogenesisAtorvastatinEndothelial precursors
2005
W16-P-060 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease
Nissen S, Tardif J, Crowe T, Thuren T, Shear C, Revkin J. W16-P-060 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease. Atherosclerosis Plus 2005, 6: 116. DOI: 10.1016/s1567-5688(05)80456-8.Peer-Reviewed Original ResearchW10-P-004 Design of a study of the effect of torcetrapib/atorvastatin versus atorvastatin alone on intima-media thickness in patients with mixed hyperlipidemia
Bots M, Riley W, Evans G, Kastelein J, Revkin J, Thuren T, Shear C, Nguyen T. W10-P-004 Design of a study of the effect of torcetrapib/atorvastatin versus atorvastatin alone on intima-media thickness in patients with mixed hyperlipidemia. Atherosclerosis Plus 2005, 6: 48. DOI: 10.1016/s1567-5688(05)80191-6.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply